New Analyses From Pivotal Phase 3 Studies Show Kyprolis® (Carfilzomib) Allows Patients With Relapsed Multiple Myeloma To Live Longer Without Disease Progression
Cumulative Rates of Complete Response or Better Increased Over Time in Patients Treated With Kyprolis in Combination With Lenalidomide and Dexamethasone (KRd)
In a Post-Hoc Analysis, Treatment With KRd for 18 Months Reduced Risk of Progression or Death by 42 Percent During That Period
Additional Analyses Showed Kyprolis Plus Dexamethasone (Kd) was Superior to Bortezomib Plus Dexamethasone (Vd) Across Patient Populations
THOUSAND OAKS, Calif., June 10, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a post-hoc analysis of the pivotal Phase 3 ASPIRE study which highlighted the benefit of conti...
Source: Amgen News Release - June 10, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
ASCO: Pembrolizumab Plus Lenalidomide Gets Response in MM (CME/CE)
(MedPage Today) -- Combo shows signs of benefit in relapsed/refractory myeloma (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - June 9, 2016 Category: Consumer Health News Source Type: news
New Phase 3 Secondary Analysis Shows Progression-Free Survival Benefit In Early Relapsing Multiple Myeloma Patients Treated With Kyprolis® (Carfilzomib)-Based Regimen
Analysis Assessed Efficacy and Safety of Kyprolis in Combination With Lenalidomide and Dexamethasone (KRd) Using Results From Pivotal ASPIRE Trial
THOUSAND OAKS, Calif., June 6, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced data from a secondary analysis of the pivotal Phase 3 ASPIRE trial that showed Kyprolis® (carfilzomib) for Injection in combination with lenalidomide and dexamethasone (KRd) improved progression-free survival (PFS) and overall response rate (ORR) compared to lenalidomide and dexamethasone (Rd) alone in patients with relapsed multiple myeloma with early disease progression after initial...
Source: Amgen News Release - June 6, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Lenalidomide maintenance therapy improves overall survival for patients with multiple myeloma
Lenalidomide maintenance following stem cell transplant now a standard of care for people with multiple myeloma (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 5, 2016 Category: Science Source Type: news
Kyprolis® (Carfilzomib) Demonstrates Economic Value In Relapsed Or Refractory Multiple Myeloma Manuscript Published In "Journal of Medical Economics"
Analysis Based on Head-to-Head Trial Shows Kyprolis With Lenalidomide and Dexamethasone Offers Substantial Value Over Previous Standard of Care in Relapsed or Refractory Multiple Myeloma
THOUSAND OAKS, Calif., May 26, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Kyprolis Global Economic Model (K-GEM)1 has been published in the Journal of Medical Economics showing that in the United States (U.S.), Kyprolis® (carfilzomib) in combination with lenalidomide and dexamethasone (KRd) is cost-effective compared to lenalidomide and dexamethasone (Rd) alone in patients with relapsed or refractory multiple ...
Source: Amgen News Release - May 26, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Elotuzumab Approved in Europe for Multiple Myeloma
The European Commission approved elotuzumab (Empliciti) for use in combination with lenalidomide (Revlimid) and dexamethasone for patients with multiple myeloma following progression on at least 1 prior therapy. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - May 13, 2016 Category: Hematology Source Type: news
Maintenance Tx in MM: No Advantages With Revlimid (CME/CE)
(MedPage Today) -- Lenalidomide not superior to thalidomide for survival rates (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 15, 2016 Category: Hematology Source Type: news
Lenalidomide trials show potential for expanding lymphoma, leukaemia indications
Positive findings from two clinical trials have been published for the immunomodulatory agent lenalidomide in patients with heavily pretreated mantle cell lymphoma, and in adults with T-cell leukaemia–lymphoma or peripheral T-cell lymphoma. (Source: MedWire News)
Source: MedWire News - February 21, 2016 Category: Consumer Health News Tags: Leukaemia Source Type: news
New drug treatment Kyprolis® (carfilzomib) for relapsed multiple myeloma launches in the UK
In a clinical trial, relapsed patients treated with carfilzomib in combination with lenalidomide and dexamethasone lived 8.7 months longer without disease progression compared with lenalidomide and dexamethasone alone (Source: Pharmacy Europe)
Source: Pharmacy Europe - February 16, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Oncology Patient care Research ASPIRE study carfilzomib ENDEAVOR study Latest News multiple myeloma rare blood cancer Source Type: news
European Medicines Agency Pushes for Empliciti for the Treatment of Multiple Myeloma
The Committee for Medicinal Products for Human Use (CHMP) reviewed the monoclonal antibody Empliciti® (elotuzumab) as part of the European Medicine Agency's (EMA) accelerated assessment program. After review, CHMP recommended that Empliciti® should be used in combination with lenalidomide and dexamethasone for multiple myeloma patients who have received at least one prior therapy. This EMA recommendation will be sent to the European Commission of the European Union, the body that will make the final decision on authorizing the marketing of Empliciti®'s use. To learn more, click HERE. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - February 4, 2016 Category: Hematology Source Type: news
FDA Approves New Kyprolis® (Carfilzomib) Combination Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma
Pivotal Head-To-Head ENDEAVOR Study Shows Kyprolis and Dexamethasone Doubled Progression-Free Survival Versus Velcade® (Bortezomib) and Dexamethasone
Kyprolis Label Expansion Represents Critical Advancement for Patients With Relapsed or Refractory Multiple Myeloma, Offering New Option For Backbone Therapy
Approval Expands Kyprolis Indication and Converts Monotherapy Indication to Full Approval
THOUSAND OAKS, Calif., Jan. 21, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomi...
Source: Amgen News Release - January 21, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
